{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T01:53:39Z","timestamp":1789610019537,"version":"build-2803163510"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,4,17]],"date-time":"2020-04-17T00:00:00Z","timestamp":1587081600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,4,17]],"date-time":"2020-04-17T00:00:00Z","timestamp":1587081600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Urol"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>DA-8010 is a novel compound developed for the treatment of overactive bladder (OAB) and urinary incontinence. The aims of this study were to investigate the effects of DA-8010 on OAB in a rat model.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>Study animals were divided into the following five groups of seven animals each: a sham-operated control group, a control group with partial bladder outlet obstruction (BOO) (OAB group), and three DA-8010 (doses of 0.3\u2009mg\/kg\/day, 1\u2009mg\/kg\/day, and 3\u2009mg\/kg\/day, respectively) with partial BOO groups. Oral administration of the drugs was continued for 14\u2009days after 2\u00a0weeks of partial BOO. After 4\u00a0weeks of partial BOO, cystometrography was performed in all groups. Additionally, pro-inflammatory cytokines, Rho-kinases, and histology of the bladder were analyzed.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>There was a significant increase in the contraction interval and a decrease in contraction pressure in the 3\u2009mg\/kg\/day DA-8010 group versus those in the OAB group. Rho kinase was also significantly decreased in the DA-8010 3\u2009mg\/kg\/day dosage treatment group. The increased ratio of collagen to smooth muscle after partial BOO was significantly attenuated in the DA-8010 3\u2009mg\/kg\/day dosage group.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusions<\/jats:title>\n<jats:p>Oral administration of DA-8010 at 3\u2009mg\/kg\/day improved findings in an OAB rat model induced by partial BOO. Our results suggest that the novel muscarinic receptor antagonist DA-8010 may be a promising drug for treating patients with OAB.<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s12894-020-00611-8","type":"journal-article","created":{"date-parts":[[2020,4,17]],"date-time":"2020-04-17T11:02:58Z","timestamp":1587121378000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["The effects of oral administration of the novel muscarinic receptor antagonist DA-8010 on overactive bladder in rat with bladder outlet obstruction"],"prefix":"10.1186","volume":"20","author":[{"given":"Jin Bong","family":"Choi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seung Hwan","family":"Jeon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eun Bi","family":"Kwon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Woong Jin","family":"Bae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyuk Jin","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"U-Syn","family":"Ha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung-Hoo","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji Youl","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sae Woong","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,4,17]]},"reference":[{"key":"611_CR1","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/S0090-4295(02)02243-4","volume":"61","author":"P Abrams","year":"2003","unstructured":"Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U, et al. The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the international continence society. Urology. 2003;61:37\u201349.","journal-title":"Urology."},{"key":"611_CR2","doi-asserted-by":"publisher","first-page":"23","DOI":"10.5213\/inj.2012.16.1.23","volume":"16","author":"W Sung","year":"2012","unstructured":"Sung W, You H, Yoon TY, Lee SJ. Socioeconomic costs of overactive bladder and stress urinary incontinence in Korea. Int Neurourol J. 2012;16:23\u20139.","journal-title":"Int Neurourol J"},{"key":"611_CR3","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1093\/ageing\/afu096","volume":"43","author":"C Fox","year":"2014","unstructured":"Fox C, Smith T, Maidment I, Chan WY, Bua N, Myint PK, et al. Effect of medications with anti-cholinergic properties on cognitive function, delirium, physical function and mortality: a systematic review. Age Ageing. 2014;43:604\u201315.","journal-title":"Age Ageing"},{"key":"611_CR4","first-page":"337","volume":"2","author":"S Lam","year":"2007","unstructured":"Lam S, Hilas O. Pharmacologic management of overactive bladder. Clin Interv Aging. 2007;2:337\u201345.","journal-title":"Clin Interv Aging"},{"key":"611_CR5","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1111\/bcp.12617","volume":"80","author":"K Ruxton","year":"2015","unstructured":"Ruxton K, Woodman RJ, Mangoni AA. Drugs with anticholinergic effects and cognitive impairment, falls and all-cause mortality in older adults: a systematic review and meta-analysis. Br J Clin Pharmacol. 2015;80:209\u201320.","journal-title":"Br J Clin Pharmacol"},{"key":"611_CR6","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/j.ejphar.2018.11.037","volume":"843","author":"MJ Lee","year":"2019","unstructured":"Lee MJ, Moon JH, Lee HK, Cho CH, Choi SH, Im WB. Pharmacological characterization of DA-8010, a novel muscarinic receptor antagonist selective for urinary bladder over salivary gland. Eur J Pharmacol. 2019;843:240\u201350.","journal-title":"Eur J Pharmacol"},{"key":"611_CR7","doi-asserted-by":"publisher","first-page":"R896","DOI":"10.1152\/ajpregu.00046.2011","volume":"301","author":"LH Jin","year":"2011","unstructured":"Jin LH, Andersson KE, Han JU, Kwon YH, Park CS, Shin HY, et al. Persistent detrusor overactivity in rats after relief of partial urethral obstruction. Am J Physiol Regul Integr Comp Physiol. 2011;301:R896\u2013904.","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"611_CR8","doi-asserted-by":"publisher","first-page":"137","DOI":"10.5534\/wjmh.2016.34.2.137","volume":"34","author":"WH Kim","year":"2016","unstructured":"Kim WH, Bae WJ, Park JW, Choi JB, Kim SJ, Cho HJ, et al. Development of an improved animal model of overactive bladder: Transperineal ligation versus Transperitoneal ligation in male rats. World J Mens Health. 2016;34:137\u201344.","journal-title":"World J Mens Health."},{"key":"611_CR9","doi-asserted-by":"publisher","first-page":"153","DOI":"10.5534\/wjmh.17010","volume":"36","author":"SJ Kim","year":"2018","unstructured":"Kim SJ, Jeon SH, Kwon EB, Jeong HC, Choi SW, Bae WJ, et al. Improvement of persistent detrusor Overactivity through treatment with a Phytotherapeutic agent (WSY-1075) after relief of bladder outlet obstruction. World J Mens Health. 2018;36:153\u201360.","journal-title":"World J Mens Health."},{"key":"611_CR10","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1111\/j.1464-410X.2006.06643.x","volume":"99","author":"J Nishiguchi","year":"2007","unstructured":"Nishiguchi J, Kwon DD, Kaiho Y, Chancellor MB, Kumon H, Snyder PB, et al. Suppression of detrusor overactivity in rats with bladder outlet obstruction by a type 4 phosphodiesterase inhibitor. BJU Int. 2007;99:680\u20136.","journal-title":"BJU Int"},{"key":"611_CR11","unstructured":"National Research Council Committee for the Update of the Guide for the C, Use of Laboratory A. The National Academies Collection: Reports funded by National Institutes of Health. In: th, editor. Guide for the Care and Use of Laboratory Animals. Washington (DC): National Academies Press (US) National Academy of Sciences.; 2011."},{"key":"611_CR12","doi-asserted-by":"crossref","unstructured":"Kim SJ, Jeon SH, Kwon EB, Jeong HC, Choi SW, Bae WJ, et al. Improvement of persistent detrusor Overactivity through treatment with a Phytotherapeutic agent (WSY-1075) after relief of bladder outlet obstruction. World J Mens Health. 2018;36(2):153\u201360.","DOI":"10.5534\/wjmh.17010"},{"key":"611_CR13","doi-asserted-by":"publisher","first-page":"150","DOI":"10.5534\/wjmh.2013.31.2.150","volume":"31","author":"BI Yoon","year":"2013","unstructured":"Yoon BI, Bae WJ, Kim SJ, Kim HS, Ha US, Sohn DW, et al. The anti-inflammatory effects of a new herbal formula (WSY-1075) in a nonbacterial prostatitis rat model. World J Mens Health. 2013;31:150\u20136.","journal-title":"World J Mens Health."},{"key":"611_CR14","doi-asserted-by":"publisher","first-page":"73","DOI":"10.5534\/wjmh.2015.33.2.73","volume":"33","author":"WJ Bae","year":"2015","unstructured":"Bae WJ, Ha US, Choi JB, Kim KS, Kim SJ, Cho HJ, et al. Protective effects of KH-204 in the bladder of androgen-deprived rats. World J Mens Health. 2015;33:73\u201380.","journal-title":"World J Mens Health."},{"key":"611_CR15","first-page":"531","volume":"48","author":"RM Eglen","year":"1996","unstructured":"Eglen RM, Hegde SS, Watson N. Muscarinic receptor subtypes and smooth muscle function. Pharmacol Rev. 1996;48:531\u201365.","journal-title":"Pharmacol Rev"},{"key":"611_CR16","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1016\/S0024-3205(97)00433-5","volume":"61","author":"FJ Ehlert","year":"1997","unstructured":"Ehlert FJ, Ostrom RS, Sawyer GW. Subtypes of the muscarinic receptor in smooth muscle. Life Sci. 1997;61:1729\u201340.","journal-title":"Life Sci"},{"key":"611_CR17","doi-asserted-by":"publisher","first-page":"e1251","DOI":"10.1016\/j.juro.2016.12.022","volume":"197","author":"MS Choo","year":"2017","unstructured":"Choo MS, Moon J-H, Lee HK, Lee MJ, Lee SH, Han JH, et al. MP94-14 urodynamic evaluation of da-8010 in conscious rats with partial bladder outlet obstruction. J Urol. 2017;197:e1251.","journal-title":"J Urol"},{"issue":"Suppl 1","key":"611_CR18","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1111\/j.1464-410X.2005.05652.x","volume":"96","author":"JI Gillespie","year":"2005","unstructured":"Gillespie JI. A developing view of the origins of urgency: the importance of animal models. BJU Int. 2005;96(Suppl 1):22\u20138.","journal-title":"BJU Int"},{"key":"611_CR19","doi-asserted-by":"publisher","first-page":"2253","DOI":"10.1016\/S0022-5347(01)62305-X","volume":"160","author":"P Lluel","year":"1998","unstructured":"Lluel P, Duquenne C, Martin D. Experimental bladder instability following bladder outlet obstruction in the female rat. J Urol. 1998;160:2253\u20137.","journal-title":"J Urol"},{"key":"611_CR20","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1186\/s12906-015-0898-7","volume":"15","author":"H Lai","year":"2015","unstructured":"Lai H, Tan B, Liang Z, Yan Q, Lian Q, Wu Q, et al. Effect of the Chinese traditional prescription Suo Quan wan on TRPV1 expression in the bladder of rats with bladder outlet obstruction. BMC Complement Altern Med. 2015;15:424.","journal-title":"BMC Complement Altern Med"},{"key":"611_CR21","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1002\/nau.22528","volume":"34","author":"CC Maciejewski","year":"2015","unstructured":"Maciejewski CC, Tredget EE, Metcalfe PD. Urodynamic improvements following oral medical therapy for partial bladder outlet obstruction in an animal model. Neurourol Urodyn. 2015;34:286\u201391.","journal-title":"Neurourol Urodyn"},{"key":"611_CR22","doi-asserted-by":"publisher","first-page":"20246","DOI":"10.1074\/jbc.271.34.20246","volume":"271","author":"M Amano","year":"1996","unstructured":"Amano M, Ito M, Kimura K, Fukata Y, Chihara K, Nakano T, et al. Phosphorylation and activation of myosin by rho-associated kinase (rho-kinase). J Biol Chem. 1996;271:20246\u20139.","journal-title":"J Biol Chem"},{"key":"611_CR23","doi-asserted-by":"publisher","first-page":"12257","DOI":"10.1074\/jbc.272.19.12257","volume":"272","author":"Y Kureishi","year":"1997","unstructured":"Kureishi Y, Kobayashi S, Amano M, Kimura K, Kanaide H, Nakano T, et al. Rho-associated kinase directly induces smooth muscle contraction through myosin light chain phosphorylation. J Biol Chem. 1997;272:12257\u201360.","journal-title":"J Biol Chem"},{"key":"611_CR24","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1038\/nrm1587","volume":"6","author":"KL Rossman","year":"2005","unstructured":"Rossman KL, Der CJ, Sondek J. GEF means go: turning on RHO GTPases with guanine nucleotide-exchange factors. Nat Rev Mol Cell Biol. 2005;6:167\u201380.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"611_CR25","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1124\/jpet.103.063735","volume":"309","author":"T Schneider","year":"2004","unstructured":"Schneider T, Fetscher C, Krege S, Michel MC. Signal transduction underlying carbachol-induced contraction of human urinary bladder. J Pharmacol Exp Ther. 2004;309:1148\u201353.","journal-title":"J Pharmacol Exp Ther"},{"key":"611_CR26","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1111\/j.1442-2042.2012.03000.x","volume":"19","author":"T Matsui","year":"2012","unstructured":"Matsui T, Oka M, Fukui T, Tanaka M, Oyama T, Sagawa K, et al. Suppression of bladder overactivity and oxidative stress by the phytotherapeutic agent, Eviprostat, in a rat model of atherosclerosis-induced chronic bladder ischemia. Int J Urol. 2012;19:669\u201375.","journal-title":"Int J Urol"},{"key":"611_CR27","first-page":"1660","volume":"15","author":"B Zhang","year":"2018","unstructured":"Zhang B, Wei J, Wu X, Wang L, Huo H, Wang J. Clinical optimal dose of solifenacin succinate for nursing patients after transurethral resection of the prostate during the perioperative period. Exp Ther Med. 2018;15:1660\u20135.","journal-title":"Exp Ther Med"},{"key":"611_CR28","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.1111\/j.1464-410X.2010.09445.x","volume":"106","author":"PD Metcalfe","year":"2010","unstructured":"Metcalfe PD, Wang J, Jiao H, Huang Y, Hori K, Moore RB, et al. Bladder outlet obstruction: progression from inflammation to fibrosis. BJU Int. 2010;106:1686\u201394.","journal-title":"BJU Int"}],"container-title":["BMC Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12894-020-00611-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12894-020-00611-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12894-020-00611-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,16]],"date-time":"2021-04-16T23:10:19Z","timestamp":1618614619000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcurol.biomedcentral.com\/articles\/10.1186\/s12894-020-00611-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,17]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["611"],"URL":"https:\/\/doi.org\/10.1186\/s12894-020-00611-8","relation":{},"ISSN":["1471-2490"],"issn-type":[{"value":"1471-2490","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,17]]},"assertion":[{"value":"19 February 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 April 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 April 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The treatment protocol of this study was approved by the Institutional Animal Care and Use Committee of the School of Medicine, The Catholic University of Korea (CUMC-2017-0034-01) and handled according to the Korean NIH guidelines.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"41"}}